The Bates method, elixirs, potions and other cures for myopia: how do they work?

Gene expression in response to optical defocus of opposite signs reveals bidirectional mechanism of visually guided eye growth

Myopia (nearsightedness) is the most common eye disorder, which is rapidly becoming one of the leading causes of vision loss in several parts of the world because of a recent sharp increase in prevalence. Nearwork, which produces hyperopic optical defocus on the retina, has been implicated as one of the environmental risk factors causing myopia in humans. Experimental studies have shown that hyperopic defocus imposed by negative power lenses placed in front of the eye accelerates eye growth and causes myopia, whereas myopic defocus imposed by positive lenses slows eye growth and produces a compensatory hyperopic shift in refractive state. The balance between these two optical signals is thought to regulate refractive eye development; however, the ability of the retina to recognize the sign of optical defocus and the composition of molecular signaling pathways guiding emmetropization are the subjects of intense investigation and debate. We found that the retina can readily distinguish between imposed myopic and hyperopic defocus, and identified key signaling pathways underlying retinal response to the defocus of different signs. Comparison of retinal transcriptomes in common marmosets exposed to either myopic or hyperopic defocus for 10 days or 5 weeks revealed that the primate retina responds to defocus of different signs by activation or suppression of largely distinct pathways. We also found that 29 genes differentially expressed in the marmoset retina in response to imposed defocus are localized within human myopia quantitative trait loci (QTLs), suggesting functional overlap between genes differentially expressed in the marmoset retina upon exposure to optical defocus and genes causing myopia in humans. These findings identify retinal pathways involved in the development of myopia, as well as potential new strategies for its treatment.

The worldwide prevalence of myopia is predicted to increase from the current 23% to about 50% in the next three decades. Although much effort has been directed towards elucidating the mechanisms underlying refractive eye development and myopia, treatment options for myopia are mostly limited to optical correction, which does not prevent progression of myopia nor the pathological blinding complications often associated with the disease. Several experimental optics-based treatments have had only limited effect on myopia progression, and currently available drug treatments are limited and the mechanisms of action are not well understood. The development of safe and effective pharmacological treatments for myopia is urgently needed to prevent the impending myopia epidemic. The main obstacles that prevent the development of anti-myopia drugs are the uncertainties regarding the mechanisms controlling eye growth and optical development, including the molecular signaling pathways underlying it. In this study, we show that, contrary to the conventional thinking that myopic and hyperopic defocus trigger opposite changes in the same genes and pathways to guide postnatal eye growth, defocus of opposite signs affect eye growth via largely distinct retinal pathways. Knowing that myopic and hyperopic defocus signals drive eye growth in opposite directions and propagate via different pathways provides a framework for the development of new anti-myopia drugs. Myopia can be controlled pharmacologically by stimulating pathways underlying the retinal response to positive lenses and/or by suppressing pathways underlying the retinal response to negative lenses.